NCT00698906已完成2 期
Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 19-40 Years
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Anti-HBs antibody concentrations
研究概览
简要总结
This study will evaluate the immunogenicity and safety of different formulations of the HBV-MPL vaccine administered according to a 2-dose schedule and compare it to that of Engerix™-B administered according to a 3-dose schedule in order to determine the optimal dose of each component of the candidate HBV-MPL vaccine when administered at 0 and 6 months
详细描述
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age: between 19 and 40 years old.
- •Good physical condition as established by clinical examination and history taking at the time of entry.
- •Female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period.
- •Written informed consent obtained from the subjects
排除标准
- •Positive titres at screening for anti-hepatitis antibodies.
- •Elevated serum liver enzymes.
- •History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease.
- •Any acute disease at the moment of entry.
- •Chronic alcohol consumption.
- •Hepatomegaly, right upper quadrant abdominal pain or tenderness.
- •Any chronic drug treatment, including any treatment with immunosuppressive drugs, which in the investigator's opinion, precludes inclusion into the study.
- •History of allergic disease likely to be stimulated by any component of the vaccine.
- •Simultaneous participation in any other clinical trial.
- •Previous vaccination with a hepatitis B vaccine.
- •Previous vaccination with an MPL containing vaccine.
- •Administration of immunoglobulins in the past 3 months and during the whole study period
- •Vaccination one month before and one month after each dose of the study vaccine
研究组 & 干预措施
Group A
Experimental
干预措施: HBV-MPL vaccine (Biological)
Group B
Experimental
干预措施: HBV-MPL vaccine (Biological)
Group C
Experimental
干预措施: HBV-MPL vaccine (Biological)
Group D
Experimental
干预措施: HBV-MPL vaccine (Biological)
Group E
Experimental
干预措施: HBV-MPL vaccine (Biological)
Group F
Active Comparator
干预措施: Engerix™-B (Biological)
结局指标
主要结局
Anti-HBs antibody concentrations
时间窗: Month 7
次要结局
- Occurrence, intensity and relationship to vaccination of unsolicited symptoms(31-day follow-up after vaccination)
- Anti-HBs antibody concentrations(Month 1, 2 and 6)
- Incidence of serious adverse events(During the study period)
- Occurrence, intensity and relationship to vaccination of solicited local and general symptoms(4-day follow-up after vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).Hepatitis BNCT00697216GlaxoSmithKline340
已完成
2 期
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 yHepatitis BNCT00698555GlaxoSmithKline163
已完成
2 期
Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy AdolescentsHepatitis BNCT00697775GlaxoSmithKline200
已完成
3 期
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older AdultsHepatitis BNCT00697242GlaxoSmithKline362
已完成
3 期
Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B VaccineHepatitis BNCT00697970GlaxoSmithKline321